Which challenges do entrepreneurs face when setting up and establishing a CRO in Europe or Asia? This essential question will be answered by our CEO Dr. Dimitrios Tzalis in the Life Science Get2Gether (LSG2G) Podcast hosted by Christian Soschner.
Read more
CARDIOMYO, the European consortium project led by ZeClinics and its partners Taros Chemicals and Amsterdam University Medical Centers, has been awarded with a budget of 2,4 million euros from the prestigious EUREKA- EUROSTARS innovation program.
A consortium comprising Grünenthal, Taros Chemicals and three research groups from the Institute for Neurosciences and Medicine (INM) of the Research Centre Jülich employed positron emission tomography (PET) as imaging method to investigate the interaction of a single drug with two specific targets…
Cardiovascular diseases are still one of the most frequent causes of death. Since the heart muscle cannot regenerate itself, the tissue is usually remodeled leading to impaired heart function in the long term. Many patients who have survived a heart attack suffer from cardiac insufficiency years later…
Taros EVP Youri R. Mesmoudi was interviewed in the current Issue of CHEManager´s Section Chemistry & Life Sciences on “From Idea to Product – the principle of an extended workbench accelerates innovation in chemistry”
Due to current situation with the spread of the Sars-CoV-2 (“Coronavirus”) we want to share with you the latest information on how Taros Chemicals have prepared for both, the protection of our employees and partners’ health and the uninterrupted continuation of our chemistry and discovery services to our clients…
Ahead of Oxford Global’s R&D Series Drug Discovery Virtual on 29-30 July 2020 in Berlin, Germany, Oxford Global spoke to Torsten Hoffmann of Taros Chemicals about his work in Pharmaceutical R&D and the opportunities and challenges in Drug Discovery…
I3-STM dealt with a new, tailor-made immunotherapeutic approach using small antibody mimetics synthesized for the therapy of triple-negative breast cancer (TNBC), which is still insufficiently treated with the classic methods. These drugs consist of components that stimulate the immune system and…
A research cooperation of the Paracelsus Medical University Salzburg and the Paris Lodron University Salzburg co-founded a „Transfer Center for Extracellular Vesicles – Theralytic Technologies“ (EV-TT) to conduct fundamental and…
Taros’ CEO invited to speak on the exclusive Podcast of the XPOMET© Medicinale in Berlin, 10 – 12 Oct 2019. In the light of Dimitrios presenation at the XPOMET© Medicinale, he was invited to give a pre-talk about his opinion on the transformation of the drug discovery process and his activities to contribute to that…
